Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingBMY
Biotech & Genomic Medicine▲
Bristol-Myers Squibb to Spend $2.3 Billion on Houston Plant
Bristol-Myers Squibb announced on August 10 that it will invest about $2.3 billion in a new manufacturing plant in Houston, part of a larger $40 billion U.S. investment pledge. The roughly 600,000-square-foot campus will produce small-molecule medicines, biologics, and antibody-drug conjugates, and is expected to create close to 500 skilled jobs and about 2,000 construction jobs between 2027 and 2030. Texas is providing $4.89 million in state funding for the project. The move comes as drugmakers including Eli Lilly, Johnson & Johnson, and Pfizer expand U.S. manufacturing amid tariff pressure from the Trump administration. Separately, British regulators cleared Eli Lilly's weight-loss pill Foundayo for weight management and type 2 diabetes, making the UK the first country in Europe to approve the drug.
Bristol Myers Raises 2026 Outlook on Eliquis Strength
Bristol Myers Squibb raised its full-year 2026 revenue guidance to $49-$50 billion, up from $46-$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis revenue growth of 20-25% for the year, versus a prior 10-15% forecast, and legacy portfolio revenues to decline 4-6% instead of 12-16%. Eliquis, co-commercialized with Pfizer, posted 22% growth in the second quarter, helping offset generic erosion for Revlimid, Pomalyst, Sprycel and Abraxane. Management still expects Eliquis sales to decline by $1.5-$2 billion in 2027.
Bristol Myers Squibb Partners With Chai Discovery on AI Antibody Discovery
Bristol Myers Squibb announced a new collaboration with Chai Discovery to advance AI-driven therapeutic antibody discovery. The agreement focuses on using artificial intelligence and machine learning to support the identification of novel therapeutic antibody candidates. The move reflects Bristol Myers Squibb's effort to integrate advanced computational tools into its drug discovery work. Investors should watch for pipeline updates where the company attributes new antibody programs or faster candidate selection to this AI system.
Corcept Leads Branded Pharma Q2 With 21.6% Revenue Beat
Corcept Therapeutics reported second-quarter revenues of $256.1 million, up 31.7% year on year and beating analysts' expectations by 21.6%, making it the standout performer among eight branded pharmaceutical stocks tracked. The company also beat EPS estimates and raised full-year revenue guidance above expectations, with its stock up 28.1% since reporting to trade at $119.05. Bristol-Myers Squibb posted revenues of $12.97 billion, up 5.7% and 12.9% above estimates, while Eli Lilly delivered the fastest revenue growth at 47.7% to $22.97 billion, beating by 11.4%. Zoetis was the weakest, with flat revenues of $2.47 billion missing estimates by 1.5% and lowering full-year guidance. Supernus Pharmaceuticals reported $211.3 million in revenue, up 27.7% and 2.8% above estimates.
Seaport Therapeutics IPO Draws Big Pharma Attention
Seaport Therapeutics has emerged as a potential acquisition target for major pharmaceutical companies following its May 2026 IPO. The company's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for major depressive disorder and topline results expected in the first half of 2027. Bristol Myers Squibb, which previously paid $14 billion for Karuna Therapeutics co-founded by Seaport CEO Daphne Zohar, is ranked as the top potential acquirer. Johnson & Johnson, AbbVie, and Sanofi are also named as plausible buyers. Seaport completed an upsized $260 million IPO and holds $427.26 million in cash, guiding to a runway into 2029.
Healthcare ETFs Hit One-Year Highs on Earnings and M&A
Healthcare ETFs are hitting one-year highs as the sector benefits from improving earnings visibility, attractive relative valuations, and a rotation out of overcrowded AI and tech trades into defensive growth. State Street Health Care Select Sector SPDR ETF XLV has surged 6.6% over the past month compared with 3.4% gains for State Street SPDR S&P 500 ETF Trust SPY. S&P 500 healthcare companies are expected to deliver double-digit earnings growth from Q4 2026 through 2027, and the sector is expected to log a 21.2% increase in earnings on 2.2% higher revenues, according to Zacks Sector and Market Earnings Trends issued on Aug. 12, 2026. M&A value in the sector has touched nearly $284 billion this year, approaching 2025's total of $306 billion, and hedge fund bets in favor of healthcare stocks recently neared a five-year high, per a Goldman Sachs note. The FDA has accelerated its approval process, with the annual number of new drug approvals in 2025 reaching its highest level since 2020.
Hematogenix assay underpins FDA accelerated approval of Bristol Myers Squibb's ZENBEXUS
Hematogenix announced that its proprietary Next Generation Flow Cytometry assay for multiple myeloma minimal residual disease served as the analytical method for the pivotal efficacy endpoint supporting the FDA's accelerated approval of Bristol Myers Squibb's ZENBEXUS (iberdomide), the first CELMoD therapy approved for multiple myeloma. The FDA-approved prescribing information states that MRD-negative complete response was assessed using a Hematogenix Next Generation Flow Cytometry assay at a threshold of 10⁻⁵. In the Phase 3 EXCALIBER-RRMM trial, patients treated with ZENBEXUS in combination with daratumumab and hyaluronidase-fihj and dexamethasone achieved an MRD-negative complete response rate of 41%, compared with 21% for patients treated with daratumumab, bortezomib, and dexamethasone, a statistically significant improvement with p<0.0001. Hematogenix President and CEO Dr. Hytham Al-Masri said being named directly in the FDA label for the first approved therapy in a novel drug class validates the precision and scientific rigor of the company's laboratory platform. Hematogenix operates CAP-accredited and CLIA certified laboratories in the United States, United Kingdom, Malaysia, and China.
Aktis Oncology, a clinical-stage radiopharmaceutical company, is seen as a potential acquisition target for Novartis, Eli Lilly, and Bristol Myers Squibb due to its alpha-emitting cancer platform and upcoming trial data. Aktis retains full worldwide rights to its miniprotein radioconjugate platform, with $517.3 million in cash and preliminary data from its lead candidate AKY-1189 expected in the first quarter of 2027. Novartis, whose Pluvicto grew 43% in Q2 2026, and Eli Lilly, already a $60 million upfront partner, rank as the top two strategic acquirers. Analysts target $34.42 for AKTS while the 24/7 Wall St. base case reaches $42.16, but a failed readout would erase the takeout premium entirely.
China Surpasses US in Drug Development, Supply Chain
China has pulled ahead of the United States in clinical drug development and supply chain, two of six domains measured in a June Cure Innovation Index survey, even as Big Pharma signs billion-dollar deals for Chinese-developed medicines. Dr. Nathan Goodyear of Williams Cancer Institute told Benzinga that roughly a third of new drugs Big Pharma licensed in came from Chinese labs, up from almost none a decade ago. Bristol Myers Squibb signed a $15.2 billion collaboration with Jiangsu Hengrui Pharmaceuticals in May covering 13 early-stage programs, while Merck reached a $2 billion licensing agreement in March 2025 for HRS-5346, a cardiovascular drug developed entirely in China. The U.S. Department of Health and Human Services launched Operation TrailBlazer in late June, and Congress introduced the Biotech Investment National Security Act to screen outbound biotech investment, building on the Biosecure Act signed into law in December 2025. The survey of 117 senior U.S. industry and academic leaders found 76% say the U.S. leads but China is closing fast, 85% say the U.S. lead lasts 10 years or less, and 72% agree China is improving faster than the U.S.
AstraZeneca and Bristol Myers Squibb Discuss Potential Mega-Merger
AstraZeneca and Bristol Myers Squibb have reportedly held talks about a potential merger, a deal that would create a pharmaceutical giant but faces significant hurdles. Analysts note AstraZeneca already has one of the strongest organic growth profiles in pharma, on track to hit $80 billion in annual sales by 2030, and a merger would force it to absorb Bristol Myers Squibb's looming patent cliff on key drugs like Eliquis. The deal could also trigger antitrust scrutiny given both companies' dominance in cancer care, and a straight cash and debt buyout is essentially impossible with Bristol Myers having deal capacity of around $32 billion and AstraZeneca around $37 billion. The discussion comes amid a perception that the current administration is more merger-friendly, potentially encouraging other big pharma companies to pursue defensive mega-mergers.
Bristol Myers Squibb is facing a revived $6.7 billion lawsuit after a federal appeals court reinstated claims tied to its Celgene acquisition. Plaintiffs allege the company deliberately delayed FDA approval of certain drugs to avoid paying contingent value rights owed to former Celgene shareholders. The appeals court decision brings renewed legal and financial uncertainty related to how the Celgene transaction was structured. The case does not directly affect the scientific strength of the pipeline or recent approvals such as ZENBEXUS, but it could influence how investors think about potential cash calls, management bandwidth and the risk premium applied to a business that is also contending with patent cliffs and pricing pressure.
Vinod Khosla Says AI Creates Hyperabundance of New Drugs but Testing Lags
Venture capitalist Vinod Khosla said artificial intelligence is rapidly expanding drug discovery, but traditional testing methods have failed to keep pace with the technology's progress. In a post on X, Khosla said AI has produced what he described as a 21st-century hyperabundance of potential new drugs and biological hypotheses, while drug testing still relies heavily on conventional animal studies. He argued that the industry needs a more human-relevant approach to evaluating potential treatments, pointing to Vivodyne, a biotechnology company developing technology to test drugs using living human tissues at scale. Khosla also said he was excited to continue working with Vivodyne as the company develops its Virtual Human data center, which he said could eventually help researchers predict how patients will respond to treatments. The article also noted that Anthropic launched Claude Science, an AI workbench for scientific research, Takeda reported its AI-developed psoriasis drug zasocitinib significantly outperformed Bristol-Myers Squibb's Sotyktu in a Phase 3 trial, and Nvidia and Eli Lilly announced a $1 billion AI co-innovation lab.
Bristol Myers Squibb Wins FDA Approval for ZENBEXUS
Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, marking the first approved CELMoD therapy in this disease setting. The approval comes as the stock trades at $64.65, with a 30-day return of 13.52%, a year-to-date return of 20.93%, and a one-year total shareholder return of 41.71%. Analysts following the most popular narrative value the stock at $62.96, about 3% below the current price, citing declining revenue but rising margins and a higher future P/E. The company's current P/E of 14.2x is below the US Pharmaceuticals industry average of 16.6x.
FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS for Multiple Myeloma
The U.S. Food and Drug Administration has granted accelerated approval to Bristol Myers Squibb's ZENBEXUS, the first CELMoD therapy, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Approval was based on Phase 3 EXCALIBER-RRMM results showing the ZDd regimen doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone, at 41% versus 21%. ZENBEXUS carries Boxed Warnings for embryo-fetal toxicity and venous and arterial thromboembolism, and is available only through a restricted REMS program. Bristol Myers Squibb also noted that a New Drug Application for mezigdomide, another investigational CELMoD, is under FDA review with a target date of May 13, 2027.
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics reported second quarter 2026 financial results and announced FDA clearance of its IND application for ATR 1072, enabling the launch of the Corventis Phase 1/2 trial in PRKAG2 syndrome. The company also earned a second milestone payment of $15 million under its global cardiovascular collaboration with Bristol Myers Squibb, which will be recorded in the third quarter. Collaboration revenue was $3.0 million for the quarter, while R&D expenses were $15.3 million and G&A expenses were $10.3 million. As of June 30, 2026, Atrium had $263.9 million in cash, cash equivalents and short-term investments, which the company believes is sufficient to fund operations through mid-2028. The Corventis trial is expected to enroll its first participant by the end of 2026, with initial proof-of-concept data anticipated in the second half of 2027.
Bristol Myers Growth Portfolio Sales Rise 13% in First Half
Bristol Myers Squibb's growth portfolio sales rose 13% in the first half of 2026, lifting its share of total revenues to 56% from 51.8% a year earlier. The portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy. Opdivo Qvantig is now generating annualized revenues of more than $1 billion. Legacy products including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane still account for 44% of revenues and face erosion from loss of exclusivity. Bristol Myers shares have gained 17.9% year to date, and the Zacks Consensus Estimate for 2026 EPS has risen to $6.81 from $6.32 over the past 60 days.
AstraZeneca and Bristol-Myers Squibb call off merger talks
The Financial Times reports that merger talks between British pharmaceutical giant AstraZeneca and US peer Bristol-Myers Squibb have been terminated. The deal would have created one of the world's largest drugmakers with a market capitalisation of around 400 billion dollars. The two sides had been nearing an agreement on a plan for AstraZeneca to buy Bristol-Myers Squibb shares at a premium, aiming for an announcement in mid-August. However, the day after the talks were reported on 3 August, AstraZeneca's board decided to call them off.
AstraZeneca shares plunge 9% on report of merger talks with Bristol-Myers Squibb
AstraZeneca shares suffered their biggest one-day drop since 2020, closing down as much as 9%, after reports emerged that the company held merger talks with U.S. rival Bristol-Myers Squibb. A combined entity would be worth close to $400 billion, making it the fourth-largest drugmaker globally by market value, though neither firm confirmed the discussions and people familiar with the matter told Reuters a deal may never materialize. Investors and analysts reacted with skepticism, with Jefferies analysts saying they were "a bit perplexed" given AstraZeneca's strong growth trajectory under CEO Pascal Soriot, who recently reiterated the company does not need M&A to reach its $80 billion annual revenue target by 2030. Union Investment's Markus Manns called the idea strategically and financially unsound, while ATG Healthcare's Lukas Leu described it as growth-dilutive in the near term. Bristol-Myers Squibb shares initially rose as much as 6% on the news, reflecting a view that the company needs a deal more urgently as its top products Eliquis and Opdivo face looming patent expirations, though BMO's Evan Seigerman warned that antitrust concerns over overlapping cancer drugs could reduce the odds of a successful merger.
Bristol Myers Squibb to build $2.3 billion Houston campus
Bristol Myers Squibb announced it will build a $2.3 billion drug manufacturing campus in Houston, Texas, as part of its broader $40 billion five-year U.S. investment commitment. The roughly 600,000-square-foot facility at Generation Park will produce small molecules, biologics, and antibody-drug conjugates, with a design allowing its production footprint to adapt to the company's pipeline. The campus is expected to employ nearly 500 people and support about 2,000 construction workers through 2030. Texas Governor Greg Abbott said the project is eligible for a $4.89 million Texas Enterprise Fund grant and meets criteria for state incentives under the Jobs, Energy, Technology and Innovation program. Bristol Myers raised its full-year revenue guidance to approximately $49 billion to $50 billion, driven by drugs including Eliquis, Camzyos, and Reblozyl.
Eli Lilly, Novo Nordisk, and Pfizer lead healthcare news after quarterly results
Eli Lilly, Novo Nordisk, and Pfizer were among the notable healthcare companies reporting quarterly results this week. Eli Lilly posted better-than-expected second-quarter results driven by its GLP-1 drugs, with revenue of $23 billion beating consensus by $2.3 billion, and raised its full-year revenue guidance to a range of $85.0 billion to $87.0 billion, though the midpoint fell short of the $85.4 billion consensus. Novo Nordisk lifted its full-year outlook for the second time this year on GLP-1 strength, now expecting sales and operating profit to decline by no more than 6% at constant exchange rates, but its U.S.-listed shares fell as much as 6%. Pfizer topped second-quarter expectations with adjusted earnings per share of $0.77 and revenue of $15.03 billion, and raised its full-year revenue guidance by $500 million at the midpoint to $60.5 billion to $62.5 billion. Merck also reported better-than-expected second-quarter results and raised its full-year revenue guidance to $66.3 billion to $67.3 billion, but lowered its adjusted earnings per share forecast to $2.66 to $2.76, below the $2.76 consensus, due to charges from its Terns acquisition. Bristol-Myers Squibb fell after a Reuters report said there are no discussions with AstraZeneca about a potential deal, contradicting earlier reports of preliminary merger talks. Integer Holdings agreed to be acquired by KKR in an all-cash deal valued at approximately $5.7 billion, with stockholders receiving $127.00 per share. The S&P 500 Health Care Index Sector gained 1.92% during the week, with Charles River Laboratories and Veeva Systems among the top gainers, while DaVita and Insulet were among the top losers.
FDA Approves Replimune's Skin Cancer Drug on Third Attempt
U.S. biopharmaceutical company Replimune Group announced it has received accelerated approval from the U.S. Food and Drug Administration for its difficult-to-treat skin cancer therapy RP1, brand name Tudriqev. The drug is intended for use in combination with Bristol Myers Squibb's cancer immunotherapy Opdivo for patients with advanced melanoma who have not responded to prior treatments. The two previous applications were rejected due to issues with trial design and insufficient evidence of efficacy. RP1 works by injecting a genetically modified herpes virus directly into tumors. The average price for one course of treatment is set at 450,000 dollars, with shipments expected to begin in about 60 days. A confirmatory late-stage clinical trial for full approval is underway, with data expected in 2030.
Alzheimer's Disease Market Projected to Reach USD 4 Billion in 2025 with 22.7% CAGR Through 2036
The Alzheimer's disease market across the seven major markets was valued at approximately USD 4 billion in 2025 and is projected to expand at a CAGR of 22.7% through 2036, according to DelveInsight. The growth is driven by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline. Key emerging therapies include Masupirdine from Suven Life Sciences, Roche's Trontinemab, Annovis Bio's Buntanetap, AB Science's Masitinib, Eli Lilly's Remternetug, Axsome Therapeutics' AUVELITY, Biovie's Bezisterim, ALZHEON's Valiltramiprosate, TauRx Therapeutics' Hydromethylthionine mesylate, Bristol Myers Squibb's COBENFY, AriBio's AR1001, Acadia Pharmaceuticals' Remlifanserin, and Cerecin's Tricaprilin. The report highlights six late-stage candidates poised to enter the market, including Masupirdine, Trontinemab, AXS-05, COBENFY, Remternetug, and Buntanetap, each with distinct mechanisms of action and anticipated clinical milestones.
Schrödinger Expands AI Co-Scientist Deal With Bristol Myers Squibb After Posting Q2 Profit
Schrödinger, Inc. reported second-quarter 2026 revenue of US$58.89 million and a shift to a US$5.98 million net profit, while expanding its collaboration with Bristol Myers Squibb to deploy its agentic AI co-scientist, Bunsen, across the partner's research organization. The expanded Bunsen agreement connects Schrödinger's new AI tool to a large existing customer, reinforcing the catalyst around deeper usage within top accounts and broader AI module adoption. Alongside the earnings turnaround, the company also highlighted an ESOP shelf registration that ties employee incentives to the success of Bunsen and related AI offerings. The investment narrative projects US$349.6 million in revenue and US$23.4 million in earnings by 2029, requiring 11.1% yearly revenue growth and a US$126.9 million earnings increase from a current loss of US$103.5 million. The biggest risk remains whether higher-value software adoption can offset ongoing margin pressures and volatile collaboration income.
Companies defy macro uncertainty and raise guidance
A growing number of companies are raising their profit outlooks despite macroeconomic uncertainty. More S&P 500 firms are lifting guidance than cutting it, and Wall Street analysts have raised third-quarter earnings estimates for the index for the second consecutive quarter. Argus research analyst Christine Dooley views consistent guidance raises as a catalyst for market-beating returns. Among the companies that have raised guidance in the second quarter so far are Cheesecake Factory, Ford, General Motors, Hasbro, Starbucks, Coca-Cola, Charles Schwab, PayPal, US Bancorp, ASML, Seagate Technology, Supermicro Computer, Bristol Myers Squibb, Johnson & Johnson, UnitedHealth Group, 3M, Lockheed Martin, Northrop Grumman, United Airlines, and United Parcel Service.
Schrödinger and Bristol Myers Squibb Strike Deal to Deploy AI Co-Scientist Bunsen for Drug Discovery
Schrödinger has entered a strategic collaboration and software agreement with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organization. The deal significantly expands BMS's use of Schrödinger's computational platform, enabling scientists to explore more possibilities, prioritize molecules with greater confidence, and accelerate discovery decisions. The collaboration includes developing novel functionality within Bunsen alongside Schrödinger's computational technologies for large-scale chemical exploration and its AI-driven synthesis planning platform RetroSynth. Bunsen is optimized to execute Schrödinger's validated, physics-based computational platform by planning and running complex molecular discovery workflows and interpreting results. BMS, a long-standing customer, will adopt Bunsen at scale, empowering a broader group of scientists to embrace a predict-first computational approach.
Global stocks surge on easing US-Iran tensions, oil drop fuels risk appetite
US stocks closed at a record high, with the Dow jumping 693.38 points after US-Iran tensions eased, sending WTI crude down over 5% and US Treasury yields lower. Communication services led the rally, surging 4.3%, driven by Meta Platforms and Alphabet, while Amazon climbed 4.6%, pushing its market value past 3 trillion dollars for the first time. In Europe, the STOXX 600 index closed up 0.45%, with aerospace and defense stocks jumping 2.7%. AstraZeneca tumbled 9% on reports of a merger deal worth over 400 billion dollars with Bristol Myers Squibb, dragging the healthcare sector down 1.7%. Asian markets mostly rose this morning, led by South Korea's KOSPI, which gained 1.5% after President Trump called off plans to strike Iran, easing energy supply and inflation concerns. The Thai stock market has a chance to recover, with BANPU resuming trading as a new entity after completing its merger with BPP, aiming to diversify away from coal and expand into data centers and energy storage systems.
AstraZeneca in advanced merger talks with Bristol Myers Squibb for $400 billion deal
AstraZeneca is reported to be in advanced merger talks with Bristol Myers Squibb, a deal that could create a combined pharmaceutical company valued at about US$400 billion. The potential transaction would rank among the largest in the sector and significantly affect competitive positions in oncology, though regulators are expected to review any agreement closely due to overlapping product portfolios. A combination would bring together large pipelines and marketed therapies in cancer, immunology, cardiovascular, and rare diseases, reshaping how AstraZeneca competes with rivals like Pfizer, Merck, and Roche. Investors are cautioned that the discussions remain in a preliminary phase, and any deal would likely require divestments to address antitrust concerns, particularly in the U.S. market where Bristol Myers is firmly established.
Dow surges to record high as US-Iran tensions ease, sending oil down over 5%
The Dow Jones Industrial Average surged to a record high on Monday after tensions between the United States and Iran eased, leading to a decline in oil prices and US Treasury yields. The Dow closed at 53,178.41, up 693.38 points or 1.32 percent. The S&P 500 ended at 7,600.50, up 1.48 percent, and the Nasdaq finished at 25,913.90, up 2.13 percent. European stocks also closed higher, supported by falling oil prices, with the STOXX 600 ending at 652.09, up 0.45 percent. However, the London market edged lower, weighed down by a sharp drop in AstraZeneca shares following reports of merger talks with Bristol Myers Squibb. West Texas Intermediate crude futures tumbled more than 5 percent to settle at 80.34 dollars a barrel after President Donald Trump announced the cancellation of plans to attack Iran and confirmed negotiations. Meanwhile, COMEX gold futures fell 16.50 dollars to close at 4,090.50 dollars an ounce, and the US dollar weakened against the yen after Japan and the United States intervened in the foreign exchange market.
FTSE 100 closes down 0.1% as AstraZeneca shares tumble on merger news
The FTSE 100 index closed 0.1% lower on Monday, weighed down by a sharp drop in AstraZeneca shares following reports of merger talks with US drugmaker Bristol Myers Squibb. AstraZeneca shares plunged 8.9%, making it the biggest faller in the index, after reports that the two companies are in discussions to create one of the world's largest pharmaceutical firms worth around 400 billion US dollars. Meanwhile, housebuilder stocks rose as UK government bond yields fell, with Vistry Group jumping nearly 8%, and Bellway and Persimmon gaining 2.8% and 2.1% respectively. Clarkson shares surged 8.9%, the most in the London market, after the company issued a positive outlook for full-year results.
European Stocks Close Higher on Falling Oil Prices and Hopes for End to Iran War
European stock markets closed higher on Monday, supported by a drop in oil prices as investors grew hopeful that diplomatic efforts to end the Iran war would resume. The STOXX 600 index closed at 652.09 points, up 2.90 points or 0.45 percent, while France's CAC-40 rose 1.22 percent, Germany's DAX gained 1.45 percent, and London's FTSE 100 slipped 0.10 percent. Crude oil futures plunged more than 4.5 percent after President Donald Trump decided to delay new strikes on Iran and push forward with a deal to limit Iran's nuclear program, as well as reopen the Strait of Hormuz. Travel and leisure stocks rose 0.6 percent, while aerospace and defense stocks surged 2.7 percent. However, AstraZeneca shares tumbled 9 percent, the biggest drop on the STOXX 600, following reports of a possible 400 billion dollar merger with Bristol Myers Squibb, dragging the healthcare sector index down 1.7 percent.
Mizuho Analyst Says AstraZeneca-Bristol Myers Deal Could Unlock Major Cost Cuts
Mizuho Securities healthcare sector specialist Jared Holz argued on CNBC that a potential acquisition of Bristol Myers Squibb by AstraZeneca could make financial sense if the combined company aggressively cuts costs. Holz said that if AstraZeneca slashes expenses and aggregates the assets, the deal is not totally unreasonable, especially if it views Bristol Myers' R&D pipeline as decent. Bristol Myers has a $2 billion cost-savings program targeting completion by the end of 2027 and trades at a discounted forward P/E of roughly 10, while AstraZeneca has a market cap of about $263 billion and Bristol Myers about $132 billion. Holz noted that Eli Lilly's $1 trillion-plus market cap is pressuring rivals like Merck to pursue deals ahead of patent cliffs, and he believes antitrust risk is low given the pharmaceutical industry's fragmentation and an administration open to large corporate deals.
Dementia-related psychosis market projected to grow at 26.2% CAGR through 2036
The dementia-related psychosis market across the seven major markets is forecast to expand at a compound annual growth rate of 26.2% from 2026 to 2036, according to a new report from DelveInsight. The market was valued at 690 million US dollars in 2025, with the United States accounting for approximately 77% of that total. More than 5 million diagnosed prevalent cases were reported across the seven major markets in 2025, including over 2 million in the US, where Alzheimer's disease dementia represented the largest share. Key therapies in development include ACP-204 from Acadia Pharmaceuticals, COBENFY from Bristol Myers Squibb, Zervimesine from Cognition Therapeutics, ML-007C-MA from Maplight Therapeutics, ITI-1284 from Johnson & Johnson, and low-dose levetiracetam from AgeneBio.
Dow futures jump 547 points ahead of busy earnings week
Dow Jones futures surged 547 points, or 1%, ahead of a busy week on Wall Street, while Nasdaq futures were flat as investors weighed whether Friday's tech rebound can continue. The S&P 500 is expected to gain 0.5% at the open. Last week, the Nasdaq rose 1% to 25,373, the S&P 500 added 0.7% to 7,489, and the Dow gained 0.5% to 52,485, recovering from a difficult July that saw the Philadelphia Semiconductor Index tumble 20.6% and the Nasdaq drop 3.2%. Attention is also on the yen, which strengthened another 0.5% to 156.60 per dollar after the first coordinated US-Japan currency intervention since 2011, with Tokyo reportedly spending almost $59 billion buying yen on Thursday. About 20% of S&P 500 companies report earnings this week, including AMD, Caterpillar, McDonald's, Eli Lilly, Disney, Uber, Airbnb, and Berkshire Hathaway. Ahead of the open, Bristol Myers Squibb shares rose over 4% on a Financial Times report that AstraZeneca is in talks to buy the US rival.
Alibaba, Bristol-Myers Squibb, and eBay lead premarket movers
Several stocks made notable premarket moves on Monday. U.S.-listed shares of Alibaba gained 4% after the company unveiled its new Qwen3.8-Max AI model, one of the most powerful in its portfolio, set for official release next week. Bristol-Myers Squibb jumped more than 5% while AstraZeneca fell more than 4% following a Financial Times report that the two pharmaceutical companies were in merger talks. eBay tumbled more than 3% after Wells Fargo downgraded the stock to underweight from equal weight, citing that the acquisition of Depop will lead to weaker earnings in fiscal year 2027 and potentially increased marketing spend. Ferguson Enterprises rose nearly 8% on news it will join the S&P 500, replacing Electronic Arts before the opening bell on Wednesday. ArcelorMittal was up more than 2% after announcing a deepened technology partnership with Microsoft, whose Azure platform will modernize the steelmaker's systems. Memory stocks were broadly lower, with SanDisk and Micron Technology down more than 3% and Seagate Technology off 2.5%. Circle Internet Group declined 5% after Morgan Stanley downgraded the stablecoin issuer to underweight, pointing to tactical and structural headwinds including a weaker outlook for USDC in circulation in 2027.
US stock futures rise on Middle East deal hopes and healthcare merger talks
U.S. stock index futures edged higher on Monday as signs of easing Middle East tensions weighed on crude prices and a potential mega-merger in healthcare lifted sentiment. Bristol Myers Squibb shares rose 8% in premarket trading after a report said it held preliminary merger talks with AstraZeneca, which could create one of the world's largest drugmakers worth nearly $400 billion, while AstraZeneca slid 6%. Brent crude fell 5.7% to $83.77 a barrel after President Trump said talks with Iran to reopen the Strait of Hormuz would occur during the day. Dow E-minis were up 329 points, or 0.63%, S&P 500 E-minis added 36.75 points, or 0.49%, and Nasdaq 100 E-minis gained 151 points, or 0.53%. Traders also looked ahead to a busy week of earnings from AI-linked companies and key labor market data, including the official non-farm payrolls report on Friday.
AstraZeneca and Bristol Myers in talks on $400 billion merger
AstraZeneca and Bristol Myers Squibb are reportedly in talks over a $400 billion deal to combine the companies, according to the Financial Times. Neither company has disclosed any details of the merger, and deal closure timelines are unclear. Both firms have significant overlap in oncology, with Bristol Myers Squibb's Opdivo and AstraZeneca's Imfinzi competing in indications including lung, kidney, bladder, and liver cancers. If completed, the megadeal would be one of the largest mergers in biotech history. For the second quarter of 2026, AstraZeneca's total revenue rose to $15.38 billion from $14.46 billion a year earlier, while Bristol Myers Squibb's revenue increased to $12.97 billion from $12.27 billion.
Bristol-Myers Raises Full-Year Outlook as Cancer Drugs Drive Q2 Beat
Bristol-Myers Squibb lifted its full-year outlook after reporting better-than-expected second-quarter 2026 results driven by higher sales of its cancer therapies. The company posted approximately $13.0 billion in revenue, beating consensus by $1.23 billion, with its growth portfolio contributing $7.6 billion. Adjusted earnings per share rose about 40% year-over-year to $2.04, exceeding estimates by $0.44. Bristol-Myers now expects full-year revenue of about $49.0 billion to $50.0 billion and adjusted EPS of $6.75 to $7.00, up from prior guidance and ahead of consensus. In other healthcare news, Johnson & Johnson agreed to pay up to $5.5 billion to settle remaining talc lawsuits alleging its products caused ovarian cancer, conditioned on at least 95% participation by claimants. Curium is in advanced talks to acquire Lantheus Holdings for about $7 billion upfront, with an additional $12.50 per share in contingent value rights, potentially valuing the deal at $8 billion. Boston Scientific shares slipped after its full-year outlook trailed consensus, despite second-quarter revenue of $5.4 billion beating estimates. Most Medicare Part D enrollees will face higher premiums in 2027 after the Trump administration ended a subsidy program, with three out of four seeing increases. The S&P 500 Health Care Index Sector edged up 0.12% during the week.
Bristol Myers Squibb Faces Patent Cliff That Could Undermine Its Low Valuation
Bristol Myers Squibb may not be as cheap as its valuation metrics suggest because of looming patent expirations on key drugs. The company's price-to-earnings ratio of 17.5 times is well below the pharmaceutical industry average of 25 times, and its dividend yield of 4% far exceeds the S&P 500's 1% and the sector's roughly 1.5%. However, Revlimid and Pomalyst lose patent protection in 2026, and Eliquis, co-marketed with Pfizer, follows in 2028, which will likely cause material revenue declines. The stock's low multiples could simply reflect Wall Street pricing in that patent cliff, and a turnaround hinges on whether Bristol Myers Squibb can win approvals for new blockbuster drugs from its pipeline in rare diseases, immunology, and cancer.
Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat
Bristol Myers Squibb raised its full-year revenue forecast after reporting better-than-expected second-quarter results. The drugmaker posted revenue of $12.97 billion, up 6% from a year earlier, and adjusted earnings of $2.04 per share, beating analyst estimates of $11.75 billion and $1.59 per share. The company lifted its full-year revenue guidance to approximately $49 billion to $50 billion, up from a prior range of $46 billion to $47.5 billion, and raised its adjusted earnings-per-share target to between $6.75 and $7.00. Blood thinner Eliquis brought in $4.48 billion in the quarter, up 22%, and the company now expects full-year Eliquis sales growth of 20% to 25%, more than double its previous projection. The growth portfolio, which includes newer medicines like Reblozyl, Camzyos, and Breyanzi, posted 15% revenue growth to $7.6 billion.
Bristol-Myers Squibb to Report Q2 Results Tomorrow
Bristol-Myers Squibb will report its second-quarter results before the market opens on Thursday. The company beat revenue expectations last quarter with $11.49 billion, up 2.5% year on year, but slightly missed full-year EPS guidance. For this quarter, analysts expect revenue to decline 6.3% year on year, a deceleration from flat revenue in the same period last year. Analyst estimates have been largely reconfirmed over the past 30 days, and the company has a history of exceeding Wall Street expectations. Bristol-Myers Squibb shares have risen 8.7% over the last month, outperforming the average 4.4% gain in the pharmaceuticals segment.